Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension
2023-505541-99-00Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Treprostinil palmitil inhalation powder with Placebo inhalation powder (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance at Week 16. Started Jun 2024; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2023-505541-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505541-99-00.